Ocugen Inc

NASDAQ:OCGNUnited States

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Contact Information

Headquarters

263 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355

Phone

484-328-4701

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Shankar Musunuri

Senior Vice President - Finance, Chief Accounting Officer

Jessica Crespo

Senior Vice President - Regulatory Affairs, compliance and safety

Nirdosh Jagota

Senior Vice President - Regulatory and Quality

Vijay Tammara

Director

Marna Whittington